{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:13:55Z","timestamp":1790950435175,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-10002-1","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T18:02:47Z","timestamp":1727546567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Virologic suppression rate and associated factors for third-line HIV treatment in Addis Ababa, Ethiopia"],"prefix":"10.1186","volume":"24","author":[{"given":"Abel Andargie","family":"Berhane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawibilisuma Fituma","family":"Chimdesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atalel Fentahun","family":"Awedew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahom Addisu","family":"Bekele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henok Mulatu","family":"Teferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getachew","family":"W\/Yohannes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"key":"10002_CR1","unstructured":"WHO HIV 2022: [Accessed Feb 1. 2024: https:\/\/www.who.int\/data\/gho\/data\/themes\/hiv-aids"},{"key":"10002_CR2","doi-asserted-by":"publisher","unstructured":"Sashini, Payagala. Anton Pozniak:The global burden of HIV:Clinics in Dermatology;2024, 42(2) Pages 119\u2013127, ISSN 0738-081X,:https:\/\/doi.org\/10.1016\/j.clindermatol.2024.02.001","DOI":"10.1016\/j.clindermatol.2024.02.001"},{"key":"10002_CR3","doi-asserted-by":"publisher","first-page":"1068664","DOI":"10.3389\/fpubh.2023.1068664","volume":"11","author":"X Tian","year":"2023","unstructured":"Tian X, Chen J, Wang X, Xie Y, Zhang X, Han D, Fu H, Yin W, Wu N. Global, regional, and national HIV\/AIDS disease burden levels and trends in 1990\u20132019: a systematic analysis for the global burden of disease 2019 study. Front Public Health. 2023;11:1068664. https:\/\/doi.org\/10.3389\/fpubh.2023.1068664. PMID: 36875364; PMCID: PMC9975742.","journal-title":"Front Public Health"},{"key":"10002_CR4","doi-asserted-by":"publisher","unstructured":"Katabira ET, Oelrichs RB. Scaling up antiretroviral treatment in resource-limited settings: successes and challenges. AIDS. 2007;21 Suppl 4:S5-10. https:\/\/doi.org\/10.1097\/01.aids.0000279701.93932.ef. PMID: 17620753.","DOI":"10.1097\/01.aids.0000279701.93932.ef"},{"issue":"10","key":"10002_CR5","doi-asserted-by":"publisher","first-page":"e0164619","DOI":"10.1371\/journal.pone.0164619","volume":"11","author":"A Gupta","year":"2016","unstructured":"Gupta A, Juneja S, Vitoria M, Habiyambere V, Nguimfack BD, Doherty M, Low-Beer D. Projected uptake of New Antiretroviral (ARV) Medicines in adults in low- and Middle-Income countries: a Forecast Analysis 2015\u20132025. PLoS ONE. 2016;11(10):e0164619. https:\/\/doi.org\/10.1371\/journal.pone.0164619. PMID: 27736953; PMCID: PMC5063297.","journal-title":"PLoS ONE"},{"key":"10002_CR6","doi-asserted-by":"crossref","unstructured":"Grinsztejn B, Hughes MD, Ritz J, Salata R, Mugyenyi P, Hogg E, Wieclaw L, Gross R, Godfrey C, Cardoso SW, Bukuru A, Makanga M, Faesen S, Mave V, Wangari Ndege B, Nerette Fontain S, Samaneka W, Secours R, van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Avihingsanon A, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC. A5288 Team. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. Lancet HIV. 2019;6(9):e588-e600. doi: 10.1016\/S2352-3018(19)30146-8. Epub 2019 Jul 29. PMID: 31371262; PMCID: PMC6857629.","DOI":"10.1016\/S2352-3018(19)30146-8"},{"issue":"6","key":"10002_CR7","doi-asserted-by":"publisher","first-page":"e25905","DOI":"10.1002\/jia2.25905","volume":"25","author":"A Avihingsanon","year":"2022","unstructured":"Avihingsanon A, Hughes MD, Salata R, Godfrey C, McCarthy C, Mugyenyi P, Hogg E, Gross R, Cardoso SW, Bukuru A, Makanga M, Badal-Aesen S, Mave V, Ndege BW, Fontain SN, Samaneka W, Secours R, Van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Munyanga C, Chagomerana M, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, Grinsztejn B. A5288 study team. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV\/r) and\/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. J Int AIDS Soc. 2022;25(6):e25905. https:\/\/doi.org\/10.1002\/jia2.25905. PMID: 36039892; PMCID: PMC9332128.","journal-title":"J Int AIDS Soc"},{"key":"10002_CR8","doi-asserted-by":"publisher","unstructured":"Edessa D, Sisay M, Asefa F. Second-line HIV treatment failure in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One. 2019;14(7):e0220159. https:\/\/doi.org\/10.1371\/journal.pone.0220159. Erratum in: PLoS One. 2019;14(9):e0223158. PMID: 31356613; PMCID: PMC6663009.","DOI":"10.1371\/journal.pone.0220159"},{"issue":"1","key":"10002_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12981-023-00572-6","volume":"20","author":"S SeyedAlinaghi","year":"2023","unstructured":"SeyedAlinaghi S, Afsahi AM, Moradi A, Parmoon Z, Habibi P, Mirzapour P, Dashti M, Ghasemzadeh A, Karimi E, Sanaati F, Hamedi Z, Molla A, Mehraeen E, Dadras O. Current ART, determinants for virologic failure and implications for HIV drug resistance: an umbrella review. AIDS Res Ther. 2023;20(1):74. https:\/\/doi.org\/10.1186\/s12981-023-00572-6. PMID: 37884997; PMCID: PMC10604802.","journal-title":"AIDS Res Ther"},{"issue":"3","key":"10002_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/apc.2020.0242","volume":"35","author":"A Subramanian","year":"2021","unstructured":"Subramanian A, Mohan A, Kataria S, Krishnan R. Third line antiretroviral treatment in India: Cohort Analysis and Treatment outcomes from a Public Health Facility. AIDS Patient Care STDs. 2021;35(3):69\u201374.","journal-title":"AIDS Patient Care STDs"},{"key":"10002_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12981-015-0072-9","volume":"12","author":"JA Mata-Mar\u00edn","year":"2015","unstructured":"Mata-Mar\u00edn JA, Huerta-Garc\u00eda G, Dom\u00ednguez-Hermosillo JC, Chavez-Garc\u00eda M, Banda-Lara MI, Nu\u00f1ez-Rodr\u00edguez N, Cruz-Herrera JE, Sandoval-Ram\u00edrez JL, Mart\u00ednez-Abarca I, Villag\u00f3mez-Ru\u00edz AF, Manjarrez-Tellez B, Gayt\u00e1n-Mart\u00ednez J. Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients. AIDS Res Ther. 2015;12:31. https:\/\/doi.org\/10.1186\/s12981-015-0072-9. PMID: 26413132; PMCID: PMC4582634.","journal-title":"AIDS Res Ther"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10002-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10002-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10002-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T18:02:49Z","timestamp":1727546569000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10002-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["10002"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10002-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"8 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research study obtained ethics approval from the Institutional Review Board (IRB) of Yikatit Medical College ((Protocol No.331\/2023). Additionally, the Addis Ababa City Administration\u2019s ethical review board also granted approval prior to the commencement of data collection. The clearance letter was submitted to each study site before the actual data collection for the study. Letter of cooperation was obtained from the Department of Internal Medicine. The information collected was kept anonymous and confidential. The informed consent of the patient to participate in this study was waived by an Institutional Review Board (IRB) of Yikatit Medical College (Protocol No.331\/2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1068"}}